NASDAQ:CPRX Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $16.10 +0.30 (+1.90%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$15.72▼$16.2250-Day Range$14.76▼$21.0552-Week Range$5.58▼$22.11Volume1.69 million shsAverage Volume3.36 million shsMarket Capitalization$1.68 billionP/E Ratio26.39Dividend YieldN/APrice Target$20.38 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Catalyst Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside26.6% Upside$20.38 Price TargetShort InterestHealthy10.42% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment0.80Based on 16 Articles This WeekInsider TradingSelling Shares$14.87 M Sold Last QuarterProj. Earnings Growth86.11%From $0.72 to $1.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.04 out of 5 starsMedical Sector18th out of 1,028 stocksPharmaceutical Preparations Industry7th out of 501 stocks 3.4 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.38, Catalyst Pharmaceuticals has a forecasted upside of 26.6% from its current price of $16.10.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.42% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently decreased by 3.04%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 3.8 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Catalyst Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest81 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 179% compared to the previous 30 days.MarketBeat Follows29 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 107% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,867,756.00 in company stock.Percentage Held by Insiders14.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.66% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 86.11% in the coming year, from $0.72 to $1.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 26.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.19.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 26.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.21.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 8.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Catalyst Pharmaceuticals (NASDAQ:CPRX) StockCatalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.Read More Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Stock News HeadlinesJanuary 25, 2023 | marketbeat.comPliant Therapeutics Gaps 34% Higher: More Upside To Come? (CPRX)Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.January 11, 2023 | marketbeat.com2 Biotechs Making Waves With A Single Product in their Pipeline (CPRX)Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.February 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...February 4, 2023 | americanbankingnews.comFY2023 EPS Estimates for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Boosted by AnalystFebruary 3, 2023 | finance.yahoo.comHere is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending StockFebruary 3, 2023 | americanbankingnews.comCantor Fitzgerald Weighs in on Catalyst Pharmaceuticals, Inc.'s FY2022 Earnings (NASDAQ:CPRX)February 1, 2023 | seekingalpha.comCatalyst Pharmaceuticals: Stable Upside Potential Amid Patent Infringement ConcernsJanuary 31, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitorsFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 31, 2023 | seekingalpha.comCatalyst Pharmaceuticals: Teva's Patent Challenge Of Firdapse Could Spell The End For This Cash CowJanuary 30, 2023 | finance.yahoo.comCatalyst Pharmaceutical (CPRX) Gains As Market Dips: What You Should KnowJanuary 26, 2023 | finance.yahoo.comDown 30% in a Day, Is Catalyst Pharmaceuticals Doomed?January 25, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading dayJanuary 25, 2023 | finanznachrichten.deCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA (Perampanel) CIIIJanuary 25, 2023 | msn.comHere's How Much $1000 Invested In Catalyst Pharmaceuticals 15 Years Ago Would Be Worth TodayJanuary 25, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIIIJanuary 24, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock rises Tuesday, outperforms marketJanuary 24, 2023 | msn.comCatalyst (CPRX) Down on TEVA's FDA Filing for Firdapse GenericJanuary 23, 2023 | msn.comHot Stocks: EV stocks surge; W jumps on upgrade; PLRX soars on clinical data; CPRX plungesJanuary 23, 2023 | finanznachrichten.deCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSEJanuary 23, 2023 | msn.com$1000 Invested In This Stock 10 Years Ago Would Be Worth $27,000 TodayJanuary 23, 2023 | finance.yahoo.comIs Trending Stock Catalyst Pharmaceuticals, Inc. (CPRX) a Buy Now?January 23, 2023 | finance.yahoo.com3 Reasons Growth Investors Will Love Catalyst (CPRX)January 23, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. BecerraJanuary 23, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®January 19, 2023 | finance.yahoo.comCatalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should KnowJanuary 19, 2023 | msn.comAnalyst Expectations for Catalyst Pharmaceuticals's FutureSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Company Calendar Last Earnings11/09/2022Today2/05/2023Next Earnings (Estimated)3/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees76Year Founded2002Price Target and Rating Average Stock Price Forecast$20.38 High Stock Price Forecast$24.00 Low Stock Price Forecast$15.50 Forecasted Upside/Downside+26.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.61 Trailing P/E Ratio26.39 Forward P/E Ratio22.36 P/E GrowthN/ANet Income$39.48 million Net Margins34.90% Pretax Margin44.08% Return on Equity28.53% Return on Assets24.67% Debt Debt-to-Equity RatioN/A Current Ratio6.18 Quick Ratio6.02 Sales & Book Value Annual Sales$191.76 million Price / Sales8.74 Cash Flow$0.39 per share Price / Cash Flow40.77 Book Value$2.01 per share Price / Book8.01Miscellaneous Outstanding Shares104,071,000Free Float89,397,000Market Cap$1.68 billion OptionableOptionable Beta1.17 Social Links Key ExecutivesPatrick J. McEnanyChairman, President & Chief Executive OfficerSteven R. MillerChief Operating & Scientific OfficerAlicia GrandeCFO, Treasurer, Principal Accounting Officer & VPGary IngenitoChief Medical & Regulatory OfficerStanley IyaduraiVice President-Clinical DevelopmentKey CompetitorsChinook TherapeuticsNASDAQ:KDNYDay One BiopharmaceuticalsNASDAQ:DAWNKeros TherapeuticsNASDAQ:KROSVerona PharmaNASDAQ:VRNAArcus BiosciencesNYSE:RCUSView All CompetitorsInsiders & InstitutionsFisher Asset Management LLCSold 157,329 shares on 2/3/2023Ownership: 0.128%Hancock Whitney CorpBought 14,818 shares on 2/3/2023Ownership: 0.014%Convergence Investment Partners LLCBought 7,935 shares on 2/3/2023Ownership: 0.008%Navellier & Associates Inc.Bought 4,448 shares on 2/2/2023Ownership: 0.105%ProShare Advisors LLCBought 2,027 shares on 2/2/2023Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions CPRX Stock - Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price forecast for 2023? 4 Wall Street analysts have issued 12 month price objectives for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $15.50 to $24.00. On average, they predict the company's share price to reach $20.38 in the next year. This suggests a possible upside of 26.6% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts. How have CPRX shares performed in 2023? Catalyst Pharmaceuticals' stock was trading at $18.60 on January 1st, 2023. Since then, CPRX stock has decreased by 13.4% and is now trading at $16.10. View the best growth stocks for 2023 here. When is Catalyst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023. View our CPRX earnings forecast. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. The biopharmaceutical company had revenue of $57.24 million for the quarter, compared to the consensus estimate of $53.80 million. Catalyst Pharmaceuticals had a net margin of 34.90% and a trailing twelve-month return on equity of 28.53%. What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals issued an update on its FY 2022 earnings guidance on Friday, December, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $205.00 million-$210.00 million, compared to the consensus revenue estimate of $205.03 million. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). What is Catalyst Pharmaceuticals' stock symbol? Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX." Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.40%), Artemis Investment Management LLP (0.25%), State of New Jersey Common Pension Fund D (0.13%), Fisher Asset Management LLC (0.13%), Navellier & Associates Inc. (0.11%) and Cyndeo Wealth Partners LLC (0.10%). Insiders that own company stock include Alicia Grande, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalyst Pharmaceuticals' stock price today? One share of CPRX stock can currently be purchased for approximately $16.10. How much money does Catalyst Pharmaceuticals make? Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.68 billion and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.61 on an earnings per share basis. How can I contact Catalyst Pharmaceuticals? Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933. This page (NASDAQ:CPRX) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.